Characteristics and Outcomes of Patients with Primary Central Nervous System Lymphoma

Authors

  • Hatice Terzi

Keywords:

methotrexate, overall survival, primary central nervous system lymphoma, radiotherapy

Abstract

Background: The aim of the present retrospective study was to review the clinicopathological characteristics and outcomes of primary central nervous system lymphoma (PCNSL) cases at our institute. Methods: Patients diagnosed with PCNSL at our institute from August 2010 to May 2015 were evaluated. During the said period, a total of 14 cases were diagnosed with PCNSL. Results: Deep frontal lobe was the most common site of involvement while diffuse large B-cell lymphoma (DLBCL) was the most common histological pattern. 10 patients were treated with 3.0 g/m 2 methotrexate (MTX) intravenously concomitant with intraventricular 15 mg MTX and 2 patients were treated with radiotherapy (RT). Two of the patients died due to respiratory failure a short time after the treatment started. The median overall survival (OS) was 8 months (minimum: 1 months, maximum: 15 months) and the median OS was 12.42±13.20 months (min: 1 month, max: 48 months). Conclusion: As stated in the previous studies, MTX-based chemotherapy regimens are still the most effective treatment option in this patient population.

How to Cite

Characteristics and Outcomes of Patients with Primary Central Nervous System Lymphoma. (2017). Global Journal of Medical Research, 17(13), 39-44. https://medicalresearchjournal.org/index.php/GJMR/article/view/

References

Chang-Hyun Lee, Kyu-Won Jung, Heon Yoo, Sohee Park, Seung Lee (2010) Epidemiology of Primary Brain and Central Nervous System Tumors in Korea. 48(2), 145. https://doi.org/10.3340/jkns.2010.48.2.145

Abrey LE, Ben-Porat L, Panageas KS, Yahalom J, Berkey B, Curran W (2006) Primary Central Nervous System Lymphoma: The Memorial Sloan-Kettering Cancer Center Prognostic Model. 24, 5711-5715.

Ferreri AJ, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A (2003) Prognostic Scoring System for Primary CNS Lymphomas: The International Extranodal Lymphoma Study Group Experience. 21, 266-272.

Bessell EM, Hoang-Xuan K, Ferreri AJ, Reni M (2007) Primary central nervous system lymphoma: biological aspects and controversies in management. 43, 1141-1152.

Ekenel M, Deangelis LM (2007) Treatment of primary central nervous system lymphoma. 9, 271-282.

Gerstner E, Batchelor T (2007) Primary CNS lymphoma. 7, 689-700.

Jahnke K, Thiel E (2009) Treatment options for central nervous system lymphomas in immunocompetent patients. 9, 1497-1509.

Morris PG, Abrey LE (2009) Therapeutic challenges in primary CNS lymphoma. 8, 581-92.

Nina Kadan‐lottick, Maria Skluzacek, James Gurney (2002) Decreasing incidence rates of primary central nervous system lymphoma. 95(1), 193-202. https://doi.org/10.1002/cncr.10643

Dubuisson A, Kaschten B, Lénelle J, Martin D, Robe P, Fassotte MF (2004) Primary central nervous system lymphoma report of 32 cases and review of the literature. 107, 55-63.

Shah GD, Yahalom J, Correa DD, Lai RK, Raizer JJ, Schiff D (2007) Combined Immunochemotherapy With Reduced Whole-Brain Radiotherapy for Newly Diagnosed Primary CNS Lymphoma. 25, 4730-4735.

Hormigo Gavrilovic IT, DeAngelis Yahalom J (2006) Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma. 24, 4570-4.

Omuro AM, DeAngelis LM, Yahalom J, Abrey LE (2005) Chemoradiotherapy for primary CNS lymphoma: an intent-to-treat analysis with complete follow-up. 64, 69-74.

Abrey LE, Yahalom J, DeAngelis LM (2000) Treatment for Primary CNS Lymphoma: The Next Step. 18, 3144-3150.

D. Correa, L. DeAngelis, W. Shi, H. Thaler, A. Glass, L. Abrey (2004) Cognitive functions in survivors of primary central nervous system lymphoma. 62, 548-555.

J. Crossen, D. Garwood, E. Glatstein, E. Neuwelt (1994) Neurobehavioral sequelae of cranial irradiation in adults: a review of radiation-induced encephalopathy. 12, 627-42.

L. Deangelis, F. Iwamoto (2006) An update on therapy of primary central nervous system lymphoma. 20, 1267-1285.

Bataille B, Delwail V, Menet E, Vandermarcq P, Ingrand P, Wager M (2000) Primary intracerebral malignant lymphoma: report of 248 cases. 92, 261-266.

U. Basso, A. Brandes (2002) Diagnostic advances and new trends for the treatment of primary central nervous system lymphoma. 38, 1298-1312.

Jaiswal AK, Mahapatra AK, Sharma MC (2004) Primary central nervous lymphoma presenting as bilateral cerebellopontine angle lesions: a rare case report. 11, 328-331.

Sarkar C, Sharma MC, Deb P, Singh R, Santosh V, Shankar SK (2005) Primary central nervous system lymphoma: A hospital based study of incidence and Clinicopathological feature from India (1980 -2003). 71, 199-204.

Ferreri AJ, Guerra E, Regazzi M, Pasini F, Ambrosetti A, Pivnik A (2004) Area under the curve of methotrexate and creatinine clearance are outcome-determining factors in primary CNS lymphomas. 90, 353-358.

Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan U, Hildebrand J (2003) Chemotherapy Alone as Initial Treatment for Primary CNS Lymphoma in Patients Older Than 60 Years: A Multicenter Phase II Study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. 21, 2726-2731.

Plotkin SR, Batchelor TT (2001) Primary nervous-system lymphoma. 2, 354-365.

Blay JY, Conroy T, Chevreau C, Thyss A, Quesnel N, Eghbali H (1998) High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. 16, 864-871.

Characteristics and Outcomes of Patients with Primary Central Nervous System Lymphoma

Published

2017-06-12

How to Cite

Characteristics and Outcomes of Patients with Primary Central Nervous System Lymphoma. (2017). Global Journal of Medical Research, 17(13), 39-44. https://medicalresearchjournal.org/index.php/GJMR/article/view/